Patents Examined by Donald E. Adams
  • Patent number: 5763190
    Abstract: Human immunodeficiency virus (HIV)-1, HIV-2, and simian immunodeficiency virus contain, in addition to the canonical gag/pol/env genes, additional small open reading frames encoding gene products, including the 96-amino acid 15-kDa virion associated HIV-1 Vpr gene product. The conservation of the vpr open reading frame in primate lentiviruses suggests that vpr is critical to viral replication. A biologically active recombinant HIV-1 Vpr protein was employed as a ligand to identify its cellular targets. A novel 41-kDa cytosolic protein was identified and termed the viral protein R interacting protein, or Rip-1. Rip-1 displays a wide tissue distribution, including relevant targets of HIV infection. Vpr protein induced nuclear translocation of Rip-1, as did glucocorticoid receptor (GR)-II-stimulating steroids. Vpr and Rip-1 coimmunoprecipitated with the human GR as part of a receptor complex.
    Type: Grant
    Filed: September 21, 1994
    Date of Patent: June 9, 1998
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B. Weiner, Yosef Refaeli
  • Patent number: 5753289
    Abstract: A portable food container for use in holding dry and liquid foods for consumption. The container allows an individual to consume a combination of dry cereal and cold milk in a remote location away from the kitchen without the use of a bowl and a spoon. The portable food container is inverted to allow dry cereal to flow therefrom, and squeezed to allow milk to flow therefrom.
    Type: Grant
    Filed: October 24, 1996
    Date of Patent: May 19, 1998
    Inventor: Richard B. Ness
  • Patent number: 5744368
    Abstract: This invention is directed to methods and compositions for preventing aggregation of amyloid .beta.-protein (.beta.AP) aggregation. Aggregation of amyloid .beta.-protein is associated with the deposition of amyloid in the brain. Amyloid .beta.-protein-binding compounds such as transthyretin are described which form complexes with .beta.AP and prevent formation of amyloid. This invention also identifies the serine 6 mutation in the TTR gene as predictive of person at risk for developing .beta.AP associated amyloidosis.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: April 28, 1998
    Assignee: Research Foundation of State University of New York
    Inventors: Dmitry Y. Goldgaber, Alexander L. Schwarzman, Moises Eisenberg-Grunberg
  • Patent number: 5731158
    Abstract: The present invention concerns a method to catalyze reporter deposition to improve detection or quantitation of an analyte in a sample by amplifying the detector signal which comprises reacting an analyte dependent enzyme activation system with a conjugate consisting of a detectably labeled substrate specific for the enzyme system, said conjugate reacts with the analyte dependent enzyme activation system to form an activated conjugate which deposits substantially wherever receptor for the activated conjugate is immobilized, said receptor not being reactive with the analyte dependent enzyme activation system.In another embodiment the invention concerns an assay for detecting or quantitating the presence or absence of an analyte in a sample using catalyzed reporter deposition to amplify the reporter signal.
    Type: Grant
    Filed: May 20, 1996
    Date of Patent: March 24, 1998
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Mark Norman Bobrow, Gerald Joseph Litt
  • Patent number: 5721354
    Abstract: Provided are novel Toledo and Towne human cytomegalovirus DNA sequences (HCMV) and proteins encoded thereby. The sequences are useful in methods and compositions for detecting HCMV infections and in immunogenic compositions for preventing HCMV infections.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: February 24, 1998
    Assignee: Aviron
    Inventors: Richard Spaete, Tai-An Cha
  • Patent number: 5716930
    Abstract: The invention involves secretable glial growth factors.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: February 10, 1998
    Assignees: Ludwig Institute for Cancer Research, Cambridge Neuroscience
    Inventors: Andrew David Goodearl, Paul Stroobant, Luisa Minghetti, Michael Waterfield, Mark Marchionni, Maio Su Chen, Ian Hiles
  • Patent number: 5714465
    Abstract: A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. In particular, a method for inhibiting tumor cell dissemination in a mammal comprising administering an effective amount of such metalloproteinase inhibitors is described.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: February 3, 1998
    Assignee: Amgen Inc.
    Inventors: Keith E. Langley, Yves A. DeClerck, Thomas C. Boone
  • Patent number: 5712104
    Abstract: Cancerous cells and HIV- and influenza virus-infected cells secrete .alpha.-N-acetylgalactosaminidase into blood stream, resulting in deglycosylation of Gc protein. This inactivates the MAF precursor activity of Gc protein, leading to immunosuppression. Thus, .alpha.-N-acetylgalactosaminidase activity in patient bloodstream can serve as diagnostic and prognostic index. Antibody-sandwich ELISA method and kits for cancer, HIV and influenza specific .alpha.-N-acetylgalactosaminidase as an antigen were developed to detect serum or plasma .alpha.-N-acetylgalactosaminidase in cancer and AIDS/HIV-infected and influenza patients and used as a diagnostic/prognostic index.
    Type: Grant
    Filed: January 6, 1997
    Date of Patent: January 27, 1998
    Inventor: Nobuto Yamamoto
  • Patent number: 5700635
    Abstract: A novel human immunodeficiency virus type 1 (HIV-1) cytotoxic T-lymphocyte (CTL) epitope has been identified in the gag coding region. This epitope corresponds to amino acids 255-269 of Gag and has the following sequence: NH.sub.2 -asn-pro-pro-ile-pro-val-gly-glu-ile-tyr-lys-arg-trp-ile-ile-COOH. This peptide interacts specifically with human leukocyte antigen-B8 (HLA-B8). This peptide is useful for the identification HIV-1 gag-specific CTL.
    Type: Grant
    Filed: December 19, 1994
    Date of Patent: December 23, 1997
    Assignee: United Biomedical, Inc.
    Inventors: Andrew James McMichael, Douglas Fraser Nixon, Alain Robert Michael Townsend
  • Patent number: 5695762
    Abstract: The invention resides in various peptides derived from the envelope glycoprotein of HTLV-1 and conjugates of the peptides. Compositions including the peptides are also included in the invention. The peptides, their conjugates and compositions thereof have use in diagnostic and immunization methods, especially those that are based upon T-helper and/or cytotoxic T lymphocyte function.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 9, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Akihiko Kurata
  • Patent number: 5695767
    Abstract: A Novel isolated human rotavirus is disclosed. The novel human rotavirus of the present invention has derived its genomic segments from parental strains of different genogroups and/or serotypes, and is designated as HRV 248. It has been deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, and has been assigned the ATCC accession no. VR 2274. Also disclosed are novel vaccines formulated with the human rotaviruses of the present invention, and methods of vaccinating humans against human rotaviruses of multiple serotypes with such vaccines.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 9, 1997
    Assignee: Children's Hospital Medical Center
    Inventor: Richard L. Ward
  • Patent number: 5696000
    Abstract: Disclosed herein are receptors for pathogenic or opportunistic microorganisms, methods of obtaining such reeptors, and methods of using such receptors for diagnostic or pharmaceutical purposes. The receptor comprises a substantially pure compound selected from the group consisting of GalB1-4GlcNAcB1-3GalB1-4GlcB1-1-X(R), GalB1-3GlcNAcB1-3GalB1-4GlcB1-1-X(R), GlcNAcB1-3GalB1-4GlcB1-1-X(R), GalB1-4GlcNAcB1-3GalB1-4Glc, GalB1-3GlcNAcB1-3GalB1-4Glc, GlcNAcB1-3GalB1-4Glc, GalB1-4GlcNAcB1-3Gal, and GalB1-3-GlcNAcB1-3Gal wherein X is sphingosine, hydroxylated sphingosine, or saturated sphingosine and R is H or an N-acyl fatty acid derivative of X such that X(R) is a ceramide.
    Type: Grant
    Filed: July 18, 1994
    Date of Patent: December 9, 1997
    Assignee: Antex Biologics Inc.
    Inventors: Howard C. Krivan, James E. Samuel
  • Patent number: 5695930
    Abstract: A rapid and accurate test kit is discussed for the detection of antibodies to HIV in saliva. The identification of antibodies to HIV in the saliva of seropositive individuals is shown using a test kit that requires no special machinery or skill and can be conducted by a single person in the privacy of their own home.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: December 9, 1997
    Inventors: David E. Weinstein, Trevor J. Kilpatrick
  • Patent number: 5688911
    Abstract: Trk neurotrophin binding motifs consisting of 24 amino acid, leucine rich domains are described as well as nucleic acid sequences encoding such peptides. The leucine rich motifs are useful in screens for novel agonists and antagonists of the neurotrophins.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: November 18, 1997
    Inventors: Rainer Schneider, Jorg M. Windisch
  • Patent number: 5679581
    Abstract: There are provided a method and an apparatus for measuring an immunologically active material by physically or chemically immobilizing material immunologically active to a material to be measured of a specimen to the dehydrated solid fine particles, providing a desirable dispersion comprising said immunologically active material immobilized to said solid fine particles and said specimen in a liquid medium, reacting them to cause a reaction mixture in an agglutinated state and optically measuring said agglutinated state of the reaction mixture to thereby quantitatively determine the content of said material to be measured with an improved accuracy.
    Type: Grant
    Filed: January 13, 1995
    Date of Patent: October 21, 1997
    Assignee: Canon Kabushiki Kaisha
    Inventors: Takeshi Miyazaki, Kazumi Tanaka, Masanori Sakuranaga, Tadashi Okamoto
  • Patent number: 5677135
    Abstract: Neural cells which express P75 nerve growth factor receptor (p75.sup.NTR) and which have a low resistance to .beta.-amyloid peptide toxicity are treated with a binding agent that binds with p75.sup.NTR. The resulting neural cells display an increased resistance to .beta.-amyloid peptide toxicity. Mutant and transfected neural cells are also disclosed in which the ability to express p75.sup.NTR has been removed with a resultant increase in resistance to .beta.-amyloid peptide toxicity.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: October 14, 1997
    Assignee: University of California
    Inventor: Dale E. Bredesen
  • Patent number: 5670622
    Abstract: The invention is directed to a new .mu.-conotoxin named GIIIA. .mu.-Conotoxin PIIIA consists of 22 amino residues and is found in the Eastern Pacific fish-hunting species Conus purpurascens. This conotoxin is a new Na.sup.+ channel blocker and can be used to resolve tetrodotoxin-sensitive sodium channels into three categories: 1) sensitive to .mu.-PIIIA and .mu.-conotoxin GIIIA; 2) sensitive to .mu.-PIIIA but not to .mu.-GIIIA; and 3) sensitive to neither of these two .mu.-conotoxins. In rat brain, binding competition studies between the two .mu.-conotoxins and saxitoxin suggest at least three pharmacologically distinguishable binding sites. Thus, .mu.-conotoxin PIIIA should be a key tool for distinguishing among different sodium channel subtypes.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: September 23, 1997
    Assignee: University of Utah Research Foundation
    Inventors: Ki-Joon Shon, Doju Yoshikami, Maren Marsh, Lourdes J. Cruz, David R. Hillyard, Baldomero M. Olivera
  • Patent number: 5668012
    Abstract: Novel, substantially isolated isoforms of human platelet-endothelial cell adhesion molecule-1's, DNAs coding for transcripts that encode the novel isoforms and others, including a previously identified soluble isoform, methods of using such DNAs to make isoforms by expressing the DNA's, and promoter segments controlling transcription of human platelet-endothelial cell adhesion molecule-1 genes are provided. The novel isoforms differ from the complete human platelet-endothelial cell adhesion molecule-1's in lacking one or more segments near the C-terminus encoded by exons 10-15 of the genes for the full length molecules and arise in vivo from alternative splicing of the transcript from the genes.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: September 16, 1997
    Assignee: The Blood Center Research Foundation, Inc.
    Inventors: Peter J. Newman, Richard J. Gumina, Nancy Kirshbaum
  • Patent number: 5665591
    Abstract: This invention relates to agents that regulate the proliferation of cells such as smooth muscle cells. Proliferation of smooth muscle cells may be increased or decreased by affecting the activity or concentration of a transcription factor. The factor comprises two domains of about 50 kD and about 70 kD which together have an approximate molecular weight of 120 kD and specifically binds to the nucleic acid sequence 5'-GGGTTTTCCCC-3' (SEQ ID NO 2). This factor represents a novel member of the family of rel-related factors. This invention also relates to methods for the treatment and prevention of diseases and disorders associated with proliferation of smooth muscle cells such as arteriosclerosis, fibrosis and wound healing, which involve regulation of the smooth muscle cell transcription factor.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: September 9, 1997
    Assignee: Trustees of Boston University
    Inventors: Gail E. Sonenshein, Roger Lawrence, Robert E. Bellas
  • Patent number: 5663051
    Abstract: Disclosed is an apparatus designed to be used for enriching specific cell types from cell mixtures. The apparatus includes a centrifugable device that includes a constriction defining a lower region and a defined cell separation medium. The constriction prevents mixing between the upper and lower portions of the device. Also disclosed are methods that use precisely defined cell separation media to isolate specific cells from cell mixtures, including CD34.sup.+ hematopoietic progenitor cells from blood or bone marrow, nucleated fetal cells from maternal blood, specific tumor cells, dendritic cells, natural killer cells, and natural suppressor cells from various body fluids, and for enrichment or depletion of T cell lymphocytes. Also disclosed is a density adjusted cell separation technique used to augment the above apparatus and enrichment methods. The apparatus and enrichment methods are useful in various diagnostic and therapeutic regimens.
    Type: Grant
    Filed: December 11, 1995
    Date of Patent: September 2, 1997
    Assignee: Activated Cell Therapy, Inc.
    Inventor: Peter Van Vlasselaer